- Thinly traded micro cap Clearside Biomedical (NASDAQ:CLSD) retreats 19% premarket on increased volume in response to its pending $75M public offering of common stock. Price, volume and terms have yet to be announced.
- Net proceeds will fund its pivotal Phase 3 study of suprachoroidal Zuprata for the treatment of macular edema associated with non-infectious uveitis, the initiation of its Phase 3 program of suprachoroidal Zuprata, in combination with Regeneron Pharmaceuticals' (REGN) Eylea (aflibercept), for the treatment of macular edema associated with retinal vein occlusion, the completion of certain other clinical trials, working capital and general corporate purposes.
- Yesterday's close was $11.53.